The subject of the contract was the development of an aptamer, i.e. a short chain of DNA that binds specific molecular targey – in this case a specific protein. The aptamer selection used the proprietary PureApta™ platform. The order was subject to a one-time remuneration (“upfront payment”) in the amount of PLN 214’000.
The order was accompanied by an agreement signed on February 2, 2022, guaranteeing profit sharing from the commercialization of the developed aptamer. Under this agreement, the Company will be entitled to a 6% share in the client’s net profits from commercialization of the therapeutic solution using the developed aptamer (“success fee”). Commercialization may take place through the sale or licensing of a solution at every stage of its development.
Aptamer will be used in the project of an innovative therapeutic solution with antiviral potential and it is characterized by high specificity and binding strength.
The implementation of the order opens the way to possible profit taking, which is an example of commercialization of the effects of the PureApta™ platform, created as a result of the implementation of the R&D project co-financed by European and national funds.